Gastric Cancer: Signs & Comparing Treatment Options

Common Symptoms of Stomach Cancer

Stomach cancer symptoms can vary depending on the stage of the disease. In its early stages, symptoms may be mild or easily mistaken for other gastrointestinal conditions. Below is a list of common symptoms that may indicate stomach cancer:

Persistent Indigestion or Heartburn: Ongoing discomfort in the upper abdomen or chest.

Feeling Full Quickly: A sensation of fullness after eating small amounts of food.

Bloating After Meals: Swelling or distension in the abdomen.

Unexplained Weight Loss: Losing weight without changes in diet or exercise.

Nausea and Vomiting: Frequent nausea or vomiting, sometimes with blood.

Stomach Pain: Discomfort or pain in the upper or middle abdomen.

Loss of Appetite: A decreased interest in eating or an aversion to certain foods.

Fatigue: Persistent tiredness or weakness, even with adequate rest.

Blood in Stool: Dark or tarry stools indicating possible internal bleeding.

It’s important to note that these symptoms can also be associated with less serious conditions. However, if they persist or worsen over time, consulting a healthcare provider is essential for further evaluation and diagnosis (Source: Cancer.gov).

Stomach Cancer May Be More Common Than You Think

Although stomach cancer accounts for only about 1.5% of all new cancer diagnoses in the U.S., it remains a significant concern worldwide. The American Cancer Society estimates that approximately 26,890 new cases will be diagnosed in the United States in 2024, with men facing a higher lifetime risk than women (Source: American Cancer Society). Globally, stomach cancer ranks among the leading causes of cancer-related deaths, particularly in regions such as East Asia and Eastern Europe, where prevalence rates are higher due to factors like diet and Helicobacter pylori infection (Source: National Cancer Institute).

Available Treatment Options for Stomach Cancer

A variety of treatments are available for managing stomach cancer, tailored to the disease stage and patient-specific factors. These treatments range from surgical interventions to advanced immunotherapy and targeted drug treatments. Below are three commonly used medications in stomach cancer therapy:

Keytruda (Pembrolizumab)

Keytruda is an immunotherapy drug that targets the PD-1/PD-L1 pathway, helping the immune system recognize and attack cancer cells. It is typically used for advanced stomach cancer cases, especially in patients with high microsatellite instability or PD-L1 expression.
Pros: Provides a targeted immune response, potentially leading to long-term remission in specific patient groups.
Cons: May cause immune-related side effects, such as inflammation of healthy organs, and is only effective for patients with certain biomarkers.

Vyloy

Vyloy (Zolbetuximab) is a targeted therapy for HER2-positive advanced stomach or gastroesophageal junction cancer. It works by delivering a cytotoxic agent directly to cancer cells, sparing healthy tissues.
Pros: Highly effective for HER2-positive cancers, offering improved survival rates in this subgroup.
Cons: Can cause serious side effects such as low blood cell counts and potential heart issues, limiting its use in some patients.

Opdivo (Nivolumab)

Opdivo, another immunotherapy option, blocks the PD-1 receptor to enhance the immune system’s ability to destroy cancer cells. It is often combined with chemotherapy for advanced cases of stomach or gastroesophageal cancer.
Pros: Demonstrated improved survival when used in combination with chemotherapy, offering a broader treatment scope.
Cons: Can cause severe immune-mediated side effects, including lung inflammation and colitis, requiring careful monitoring.

Ripretinib (Qinlock)

Ripretinib, sold under the brand Qinlock, is an oral “switch‑control” tyrosine‑kinase inhibitor that locks KIT and PDGFRA in an inactive conformation, enabling it to block the full spectrum of primary and resistance mutations that drive most gastrointestinal stromal tumors (GIST). It is FDA‑approved—in the United States and many other regions—for adults with advanced or metastatic GIST who have already been treated with at least three other kinase inhibitors, including imatinib, and is taken as a 150 mg tablet once daily with or without food. In the Phase 3 INVICTUS trial, ripretinib extended median progression‑free survival to 6.3 months versus 1.0 month with placebo (hazard ratio 0.15), and common adverse reactions reported in clinical use include alopecia, fatigue, nausea, abdominal pain, constipation or diarrhea, and palmar‑plantar erythrodysesthesia syndrome; clinicians also monitor for skin changes and hypertension and review potential drug or food interactions before and during therapy.

Stivarga Regorafenib

Stivarga (regorafenib) is a once‑daily, oral multikinase inhibitor approved by the FDA as a chemo‑free option for adults whose disease has already progressed despite prior therapies, specifically for metastatic colorectal cancer (mCRC), unresectable or metastatic gastrointestinal stromal tumor (GIST) after other targeted drugs, and hepatocellular carcinoma (HCC) previously treated with sorafenib. The patient‑site notes that it blocks multiple cancer‑driving pathways and is taken continuously until progression or unacceptable toxicity, with prescribers advising patients to swallow the tablets at the same time each day and avoid grapefruit products or St. John’s Wort. Because regorafenib can cause serious liver injury, bleeding, gastrointestinal perforation, and severe skin or blood‑pressure complications, liver tests and blood‑pressure monitoring are recommended and patients are told to stop the drug at least two weeks before planned surgery. Common side effects include abdominal pain, fatigue, diarrhea, decreased appetite, voice changes, elevated liver enzymes, mucositis, infection, and weight loss. Women and men of child‑bearing potential must use effective contraception during treatment and for the recommended period afterward.

Conclusion

Awareness of stomach cancer’s symptoms and prevalence can help individuals recognize potential warning signs and seek medical evaluation sooner. Early detection is critical, as it opens up more treatment options and improves overall outcomes. While treatment strategies vary based on individual needs and disease progression, advancements in targeted and immunotherapy have provided new hope for many patients. By staying informed and proactive, individuals can take important steps toward early diagnosis and effective management of this challenging condition.

---

DailyAffairsNow is for informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on DailyAffairsNow.